Vincerx Pharma Announces Inclusion in Russell 3000® and Microcap® Indexes
June 28, 2021 08:00 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
UPDATE -- Vincerx Pharma Presents Clinical Data on VIP152, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021
June 04, 2021 12:40 ET
|
Vincerx Pharma, Inc.
VIP152 shows favorable safety, on-target pharmacodynamics and signs of durable metabolic complete responses in monotherapy setting Phase 1b study in MYC-Driven relapsed/refractory aggressive...
Vincerx Pharma Presents Clinical Data on VIP512, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021
June 04, 2021 08:00 ET
|
Vincerx Pharma, Inc.
VIP152 shows favorable safety, on-target pharmacodynamics and signs of durable metabolic complete responses in monotherapy setting Phase 1b study in MYC-Driven relapsed/refractory aggressive...
Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggressive Lymphomas and Advanced Solid Tumors
June 03, 2021 16:05 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma to Participate in the Jefferies Virtual Healthcare Conference
May 26, 2021 08:00 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Reports First Quarter 2021 Financial Results and Provides a Corporate Update
May 17, 2021 08:00 ET
|
Vincerx Pharma, Inc.
Phase 1b dose escalation study of VIP152 in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021 First patient in Phase 1b Study of VIP152 in...
Vincerx Pharma Announces Completion of Public Warrant Redemption
May 06, 2021 08:00 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) (the “Company”), today announced the completion of its redemption event with respect to its outstanding public...
Vincerx Pharma Announces FDA Clearance of IND for Phase 1b Study of VIP152 in Chronic Lymphocytic Leukemia and Richter Syndrome
April 20, 2021 08:00 ET
|
Vincerx Pharma, Inc.
Dose escalation study in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021 Vincerx’s second clinical program for potential best-in-class CDK9...
Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Association for Cancer Research Annual Meeting 2021
April 10, 2021 08:31 ET
|
Vincerx Pharma, Inc.
VIP236 shows enhanced tumor targeting with robust antitumor activity across multiple xenograft models First-in-human studies on track for 1H 2022 PALO ALTO, Calif., April 10, 2021 (GLOBE NEWSWIRE)...
Vincerx Pharma To Host Key Opinion Leader Webinar on Bioconjugation and CDK9 Inhibitors for the Treatment of Hematologic and Solid Tumors
April 07, 2021 08:00 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...